Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
about
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideMolecular Imaging of Biomarkers in Breast CancerDevelopment of Companion DiagnosticsBreast cancer brain metastases: the last frontierMapping biological behaviors by application of longer-lived positron emitting radionuclidesTheragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitorsEmerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancerTissue distribution studies of protein therapeutics using molecular probes: molecular imagingManagement of solitary and multiple brain metastases from breast cancerFuture directions for the early detection of recurrent breast cancerThe use of (18)F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer.Theranostic applications of antibodies in oncology.Targeted Therapies for Brain Metastases from Breast CancerImaging metabolic heterogeneity in cancerRole of positron emission tomography for the monitoring of response to therapy in breast cancerTreatment of early-stage HER2+ breast cancer-an evolving fieldKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentTumor immunotargeting using innovative radionuclidesMechanisms of action of therapeutic antibodies for cancerC2c: turning cancer into chronic diseaseBreast Cancer Brain Metastases: Clonal Evolution in Clinical Context.Multimodality and nanoparticles in medical imagingMolecular imaging in pancreatic cancer--a roadmap for therapeutic decisions.Antibody-based imaging of HER-2: moving into the clinic.Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypesPreparation and Identification of HER2 Radioactive Ligands and Imaging Study of Breast Cancer-Bearing Nude Mice.Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis.Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasisPhase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis.Clinical impact of tumour biology in the management of gastroesophageal cancerIn vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells.Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.
P2860
Q26744088-B4F5B2E4-74D1-4515-A3FC-E7F165A81FECQ26770678-2A42A7E7-42A3-47FF-81B9-371318ACCC10Q26772870-BA711BF3-5E13-43BF-8520-2DFBBB3E919DQ26774670-34262A45-44AD-491E-A621-FAC975A01EA6Q26775663-52C86781-42A0-443B-A021-67BA6565E998Q26824070-39FCB672-CFBF-4996-A25B-5AA85EE44E0AQ26824717-A274B586-88C1-4017-AE7D-6AC9A4CC63BAQ26824799-08C26214-9769-4160-A45C-9DEC1599EADBQ26865516-17306F20-A478-48A3-8B79-56583DB4565CQ26865562-32DCADA3-709A-446E-BABD-05D8695CE45CQ27022040-205D0DD5-558D-4ED5-996E-EAF414E01BE2Q27300759-CED84104-62F9-42D1-A264-1F17F0A3227AQ27693293-64EC4DC9-A682-4D85-A913-13F6E422CDB5Q28068154-488BD985-9B82-450E-A279-C8E6E5D5CE93Q28076500-16840A41-8213-473C-8CCE-66B3950E627CQ28080621-58FC0D14-AC25-4C21-9628-085A19A58265Q28081124-A8F9F0DB-E85A-4F59-B084-6FF07F46077AQ28082880-84E16CA4-38CE-4814-9E32-16B9B2C0A89EQ28083230-721185F1-DC36-4577-95B3-AEFF297F18F5Q28385366-3A9183BD-CE15-49C1-88A3-355A8ADB8FA5Q28657973-905C2FA2-BFCC-461A-8044-D356ED4CDBF9Q30238959-C78F6534-FBB4-4904-B506-0F4DC207772EQ30407070-F3ACC126-E003-4C03-95E9-5FC62D87FECDQ30423854-F993631B-0A34-4280-A693-788542B28391Q30423880-D7D51325-716C-4058-9BB8-1231711C6BA3Q30525314-81FB04DC-6EEE-4838-AD59-AE8D5EF6C18AQ33610361-B023F580-2914-49B0-8976-2E884D85AA84Q33661325-598E5D4E-C4AF-4225-8CB5-BC05E42827B6Q33712925-8EF716CE-AD55-432F-97D6-F60C6E14B339Q33736383-91634122-9140-4F7B-9E12-05C7E3EC25B0Q33761754-E1A01D81-979D-4351-8897-58DB3A4727BEQ33823191-2E845E0D-433B-4295-A2E4-EB35C4D89435Q33841547-F9C6C15C-FCB7-4101-8E69-F067F9C77F44Q33854382-D885D610-9D5F-4472-8D50-9728822A3E85Q33867316-B71BEB4C-3368-47B9-BD23-998F2548695CQ33887412-CCC4090B-B5F4-4912-B290-B57B8693B09BQ33891408-5DAD309D-DD58-44E8-9D0F-9F992AA54794Q33922534-E6988C4E-BB20-45AF-8160-7362691EECFCQ33958666-9E7A74C9-D34E-4159-9863-564674613F36Q33974776-6BE574AD-252D-45E0-B779-3C20C236988F
P2860
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Biodistribution of 89Zr-trastu ...... with metastatic breast cancer.
@en
Biodistribution of 89Zr-trastu ...... with metastatic breast cancer.
@nl
type
label
Biodistribution of 89Zr-trastu ...... with metastatic breast cancer.
@en
Biodistribution of 89Zr-trastu ...... with metastatic breast cancer.
@nl
prefLabel
Biodistribution of 89Zr-trastu ...... with metastatic breast cancer.
@en
Biodistribution of 89Zr-trastu ...... with metastatic breast cancer.
@nl
P2093
P2860
P356
P1476
Biodistribution of 89Zr-trastu ...... with metastatic breast cancer.
@en
P2093
A H Brouwers
C P Schröder
E C Dijkers
E G de Vries
G A van Dongen
J G Kosterink
J R de Jong
M N Lub-de Hooge
T H Oude Munnink
P2860
P304
P356
10.1038/CLPT.2010.12
P407
P577
2010-03-31T00:00:00Z